Skip to main content

NCT00210808 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity


CSR Summary

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Topiramate
Product Name
TOPAMAX®
Therapeutic Area
Nutritional and Metabolic Diseases
Enrollment
407
% Female
84.2%
% White
75.7%
Product Class
Anticonvulsants
Sponsor Protocol Number
CAPSS-220
Data Holder
Johnson & Johnson
Condition Studied
Obesity
Mean/Median Age (Years)
44.0

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Data Definition Specification
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.